Clinical Trials Logo

Breakthrough Cancer Pain clinical trials

View clinical trials related to Breakthrough Cancer Pain.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT04468490 Terminated - Clinical trials for Breakthrough Cancer Pain

Treatment of Breakthrough Cancer Pain According to European Guidelines

BEG
Start date: August 11, 2020
Phase:
Study type: Observational

Pain is a frequent symptom in cancer patients with a negative impact on the quality of life (QoL).Breakthrough cancer pain (BTcP) is defined as "a transient exacerbation of pain, manifesting spontaneously or related to a specific predictable or unpredictable triggering factor, despite stable and adequately controlled basal pain". The present study assesses the percentage of patients who are treated according to the European guidelines (ESMO, 2018) for BTcP management in 4 European countries and the impact of the adherence to guidelines on patients' pain relief and QoL.

NCT ID: NCT01439919 Terminated - Pain Clinical Trials

A Clinical Trial to Assess the Clinical Benefit of SSR411298 as Adjunctive Treatment for Persistent Cancer Pain

ACT11705
Start date: January 2012
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to evaluate the efficacy of SSR411298 200 mg daily compared to placebo as adjunctive treatment for persistent cancer pain based on Numeric Rating Scale (NRS). Secondary Objectives are: - To evaluate the effect of SSR411298 200 mg daily on pain, breakthrough pain frequency, background therapy utilization, mood, patient satisfaction of pain relief, nausea, constipation, healthcare utilization and quality of life; - To evaluate the tolerability and safety of SSR411298 as adjunctive treatment for persistent cancer pain; - To characterize patient disease, in terms of cancer, cancer treatment, cancer pain and cancer pain treatment; - To evaluate the pharmacokinetic (PK) exposure of SSR411298 as adjunctive treatment for persistent cancer pain; - To assess endocannabinoid plasma concentrations.